Truist analyst Srikripa Devarakonda cut her rating on the stock to hold, after being at buy for the past 11 months. She ...
Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company’s ...
Truist analyst Srikripa Devarakonda raised the firm’s price target on Scholar Rock (SRRK) to $45 from $36 and keeps a Buy rating on the shares. Competitor Biohaven’s (BHVN) Phase 3 trial in ...
20don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price ...
Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia trials, which the firm sees as a negative for AbbVie and ...
Srikripa Devarakonda; Analyst; Truist Securities, Inc. Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion ...
Investor's Business Daily on MSN1mon
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A DowngradeAmgen stock dipped Monday after an analyst downgraded shares, saying the $5 billion opportunity for its weight-loss drug, ...
"ABBV's pain is BMY's gain," Truist Securities analyst Srikripa Devarakonda said in a note released Tuesday. "We see this as a negative for AbbVie (ABBV, Buy) and a positive for Bristol (BMY ...
Srikripa Devarakonda; Analyst; Truist Securities, Inc. Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback